Anti-Mouse CD279 (PD-1) (Clone 29F.1A12) - Purified
Code | Size | Price |
---|
LEI-P383-0.5mg | 0.5 mg | £176.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rat
Antibody Isotype: IgG2a κ
Antibody Clonality: Monoclonal
Antibody Clone: 29F.1A12
Regulatory Status: RUO
Target Species: Mouse
Applications:
- Flow Cytometry
- Immunohistochemistry- Frozen Section (IHC-F)
- Spatial Biology
- Western Blot (WB)
Shipping:
2-8°C
Storage:
This purified antibody is stable when stored at 2-8°C. Do not freeze.
Images
Further Information
Antigen Distribution:
PD-1 is expressed on a subset of CD4-CD8- thymocytes, and on activated T and B cells.
Concentration:
0.5 mg/ml
Conjugate/Tag/Label:
Purified
Format:
This purified antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Formulation:
This purified antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Immunogen:
PD-1 cDNA followed by PD-1-Ig fusion protein
Long Description:
PD-1 is a 50-55 kD member of the B7 Ig superfamily. PD-1 is also a member of the extended CD28/CTLA-4 family of T cell regulators and is suspected to play a role in lymphocyte clonal selection and peripheral tolerance. The ligands of PD-1 are PD-L1 and PD-L2, and are also members of the B7 Ig superfamily. PD-1 and its ligands negatively regulate immune responses. PD-L1, or B7-Homolog 1, is a 40 kD type I transmembrane protein that has been reported to costimulate T cell growth and cytokine production. The interaction of PD-1 with its ligand PD-L1 is critical in the inhibition of T cell responses that include T cell proliferation and cytokine production. PD-L1 has increased expression in several cancers. Inhibition of the interaction between PD-1 and PD-L1 can serve as an immune checkpoint blockade by improving T-cell responses In vitro and mediating preclinical antitumor activity. Within the field of checkpoint inhibition, combination therapy using anti-PD1 in conjunction with anti-CTLA4 has significant therapeutic potential for tumor treatments. PD-L2 is a 25 kD type I transmembrane ligand of PD-1. Via PD-1, PD-L2 can serve as a co-inhibitor of T cell functions. Regulation of T cell responses, including enhanced T cell proliferation and cytokine production, can result from mAbs that block the PD-L2 and PD-1 interaction.
NCBI Gene:
18566
Target:
PD-1
Related Products
Product Name | Product Code | Supplier | Anti-Mouse CD279 (PD-1) (Clone RMP1-14) - Purified | LEI-C2857 | Leinco Technologies | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Anti-Mouse CD279 (PD-1) (Clone RMP1-14) - Purified in vivo GOLD™ Functional Grade | LEI-P362 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Anti-Mouse CD279 (PD-1) (Clone RMP1-14) - Purified in vivo PLATINUM™ Functional Grade | LEI-P372 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Anti-Mouse CD279 (PD-1) (Clone 29F.1A12) - Purified in vivo GOLD™ Functional Grade | LEI-P377 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Anti-Mouse CD279 (PD-1) (Clone 29F.1A12) - Purified in vivo PLATINUM™ Functional Grade | LEI-P378 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Anti-Mouse CD279 (PD-1) (Clone 29F.1A12) - PE | LEI-P384 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||